HORIZANT 600 mg: Clinical Trials

2 unknown. 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	2	Unknown 2

Follow HORIZANT 600 mg: new trials by email Literature Review of HORIZANT 600 mg trials Research Report on HORIZANT 600 mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS HORIZANT 300 mg, HORIZANT 600 mg, Placebo - RLS	Phase 4	Unknown	XenoPort, Inc.	132	2016-02-01	2021-06-09
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS HORIZANT 600 mg - RLS	Phase 4	Unknown	XenoPort, Inc.	144	2016-01-01	2021-06-09

Conditions studied

Restless Legs Syndrome (2)

Sponsors

XenoPort, Inc. (2)

Countries

United States (2)

Top investigators

Steven Caras, MD (2)